Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE10A | Q9Y233 | 9/20 | 0.44 |
| ▸ | ELANE | P08246 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | PPP1CA | P62136 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.38 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | AURKA | O14965 | 1/20 | 0.36 |
| ▸ | PDE5A | O76074 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20394322 | 0.90 | PDE10A (0.45) | PDE10AELANEKMT2APPP1CALMNA | |
| SCHEMBL20406720 | 0.81 | PDE10A (0.51) | PDE10AELANE | |
| SCHEMBL20394377 | 0.81 | PDE10A (0.47) | PDE10AELANELMNASMN1; SMN2L3MBTL1 | |
| SCHEMBL20394281 | 0.81 | PDE10A (0.47) | PDE10AELANEKMT2APPP1CALMNA | |
| SCHEMBL18661517 | 0.81 | PDE10A (0.46) | PDE10AELANEKMT2APPP1CALMNA | |
| SCHEMBL20406558 | 0.80 | L3MBTL1 (0.41) | PDE10AELANEKMT2APPP1CAL3MBTL1 | |
| SCHEMBL18661457 | 0.80 | SYK (0.39) | PDE10AKMT2APPP1CAL3MBTL1 | |
| SCHEMBL18661458 | 0.80 | PDE10A (0.52) | PDE10AELANEKMT2APPP1CASMN1; SMN2 | |
| SCHEMBL20394226 | 0.80 | PDE10A (0.47) | PDE10AELANELMNASMN1; SMN2L3MBTL1 | |
| SCHEMBL18661516 | 0.80 | PDE10A (0.45) | PDE10AELANEKMT2APPP1CALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3351533-B1 | BIARYL DERIVATIVE AND MEDICINE CONTAINING SAME | KAKEN PHARMA CO LTD (JP) | 2025-07-23 | — | — | EP | disclosed |
| US-10647675-B2 | Biaryl derivative and medicine containing same | KAKEN PHARMACEUTICAL CO., LTD. (JP) | 2020-05-12 | — | — | US | disclosed |
| US-10647675-B2 | Biaryl derivative and medicine containing same | KAKEN PHARMACEUTICAL CO., LTD. (JP) | 2020-05-12 | — | — | US | disclosed |
| US-20190055199-A1 | BIARYL DERIVATIVE AND MEDICINE CONTAINING SAME | KAKEN PHARMACEUTICAL CO., LTD. (JP) | 2019-02-21 | — | — | US | disclosed |
| US-20190055199-A1 | BIARYL DERIVATIVE AND MEDICINE CONTAINING SAME | KAKEN PHARMACEUTICAL CO., LTD. (JP) | 2019-02-21 | — | — | US | disclosed |
| EP-3351533-A1 | BIARYL DERIVATIVE AND MEDICINE CONTAINING SAME | Kaken Pharmaceutical Co., Ltd. (JP) | 2018-07-25 | — | — | EP | disclosed |
| EP-3351533-A1 | BIARYL DERIVATIVE AND MEDICINE CONTAINING SAME | Kaken Pharmaceutical Co., Ltd. (JP) | 2018-07-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10647675-B2 | Biaryl derivative and medicine containing same | MAN2B1, CBR3, MANBA | PDE10A 4605/4885ELANE 1638/4885KMT2A 544/4885 |
| US-20190055199-A1 | BIARYL DERIVATIVE AND MEDICINE CONTAINING SAME | MAN2B1, CBR3, MANBA | PDE10A 4605/4885ELANE 1638/4885KMT2A 544/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.